Sign In
Get Clay Free →

Suggestions

    Ben Yerxa

    CEO at Opus Genetics

    Dr. Ben Yerxa is the CEO of Opus Genetics, a biotechnology company focused on developing treatments for rare genetic eye diseases.12 He has over 30 years of experience in the pharmaceutical and biotechnology industry, as well as in the nonprofit sector.1

    Professional Background

    Dr. Yerxa previously served as the CEO of the Foundation Fighting Blindness from 2017 to 2022.4 He has a strong background in leadership roles within the field of ophthalmology and rare genetic diseases.

    Current Role

    As the CEO of Opus Genetics, Dr. Yerxa leads the company in its mission to develop innovative treatments for rare pediatric eye disorders. Under his leadership, Opus Genetics has made significant progress in their research and development efforts:

    • The company recently received Rare Pediatric Disease Designation from the FDA for their LCA5 clinical program, which is focused on treating a specific form of inherited retinal disease.3

    Expertise and Contributions

    Dr. Yerxa is known for:

    • His extensive experience in pharmaceutical and biotechnology research
    • Leadership in nonprofit organizations dedicated to fighting blindness
    • Expertise in managing diverse teams and fostering healthy work environments5

    Dr. Yerxa is also active in the scientific community and often shares updates and insights about advancements in the field of genetic eye diseases through his professional network.23

    Related Questions

    What are Ben Yerxa's key achievements at Opus Genetics?
    How did Ben Yerxa transition from the NIH to Opus Genetics?
    What is the LCA5 clinical program at Opus Genetics?
    How does Ben Yerxa foster a healthy work environment at Opus Genetics?
    What are Ben Yerxa's views on the intersection of alcohol and work culture?
    Ben Yerxa
    Ben Yerxa, photo 1
    Ben Yerxa, photo 2
    Add to my network

    Location

    Durham, North Carolina, United States